PRO MEDICUS LIMITED (ASX:PME) has kicked off December with another significant win in the United States, signing a $25 million, seven-year contract with BayCare, one of Florida’s largest integrated delivery networks (IDNs). The agreement adds the Visage 7 Open Archive product to BayCare’s existing viewer and workflow rollout, effectively turning the system into a full-stack Visage customer ahead of a cloud migration scheduled to go live in early 2026.
The deal is built on a transaction-based model, giving the company upside as BayCare’s imaging volumes grow — and reinforcing the long-term nature of US radiology demand. For a sector usually defined by slow procurement cycles and entrenched incumbents, the pace at which PME continues to expand across North America is notable.
But behind the contract is a broader shift in how US hospital systems are thinking about imaging, cloud infrastructure and vendor consolidation — dynamics that may carry implications for other Australian med-tech and biotech companies trying to break into the world’s most complex healthcare market.
Why IDNs matter
Winning business with an IDN is strategically powerful because it creates stickiness across entire networks of hospitals, outpatient sites and specialty centres. Once a core clinical system beds in, switching becomes extremely costly. That’s why Pro Medicus’ expansion within BayCare is meaningful: archive platforms are historically the last thing US hospitals want to overhaul or move to the cloud.
The fact that BayCare is comfortable moving its imaging archive into a cloud-based Visage environment suggests confidence in the company’s performance, uptime and support capacity in-market. It also reflects a broader reality: radiology has become one of the few parts of US healthcare IT where cloud adoption is accelerating.
Cloud migration is gaining momentum
US hospitals have been slower than their European or Australian counterparts to modernise IT systems. But radiology is the outlier — image volumes keep climbing, workforce shortages are acute and providers are looking for tools that reduce hardware footprints and turnaround times.
That has pushed the economics decisively towards cloud-native systems. Archive migration was once viewed as too risky or expensive due to egress fees and latency concerns. Deals like today’s, however, show that hesitancy is fading, especially when paired with high-performance viewers, workflow tools and clear productivity gains.
This momentum is central to why PME remains so highly valued on the ASX: it sits squarely in the part of the US hospital market where budgets are still expanding rather than contracting.
Signposts for Australian biotechs
The latest Pro Medicus deal offers a few useful reminders for smaller Australian healthcare companies eyeing the US:
- Clear, measurable value wins: Pro Medicus succeeds because it cuts reporting times, reduces infrastructure costs and improves productivity — all easy for CFOs and clinical leaders to quantify. Biotechs and med-techs entering the US need similar clarity in their value propositions, whether in diagnostics, AI, software-enabled devices or workflow tools.
- Reference customers matter: US hospitals lean heavily on peer validation. Every PME deal becomes a calling card for the next procurement cycle. Emerging Australian companies will need to cultivate early regional adopters — even modest ones — if they want credibility with large systems.
- The US is moving towards cloud-first health tech: Across digital diagnostics, imaging AI, remote monitoring and informatics, cloud readiness is quickly becoming a baseline expectation. Companies that aren’t architected for this shift may find US buyers difficult to crack.
- Scale is essential: IDNs don’t want five separate tools; they want platform partners. Australian firms can benefit from pairing with US distributors or bundling complementary capabilities to look deeper than a narrow point solution.
Why this matters heading into 2026
PME’s BayCare agreement is a reminder that US hospital systems are still spending selectively — and that Australian companies can compete when the product is genuinely differentiated.
For Pro Medicus, the deal extends its North American footprint and deepens its presence in the high-value IDN market. For everyone else watching, it’s another signal that the US healthcare door isn’t closed — it just requires a product that solves a problem big enough for hospitals to care.